Evidence map›Paper›PMID 39439895›Full record

ArticleFrontiers in pharmacology2024

KHSRP knockdown inhibits papillary renal cell carcinoma progression and sensitizes to gemcitabine.

Wei Song, Heng Zhang, Yi Lu, Houliang Zhang, Jinliang Ni, Lan Chang, Yongzhe Gu, Guangchun Wang, Tianyuan Xu, Zonglin Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei Song *Department of Urology, Shanghai Shidong Hospital of Yangpu District, Shanghai, China.
Heng Zhang *Guiqian International General Hospital, Guiyang, China.
Yi Lu *Department of Urology, Shanghai Shidong Hospital of Yangpu District, Shanghai, China.
Houliang ZhangShanghai Putuo District Health Affairs Management Center, Hospital Operation Department, Shanghai, China.
Jinliang NiShanghai Putuo District Health Affairs Management Center, Hospital Operation Department, Shanghai, China.
Lan ChangShanghai Putuo District Health Affairs Management Center, Hospital Operation Department, Shanghai, China.
Yongzhe GuDepartment of Neurology, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Guangchun WangDepartment of Urology, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Tianyuan XuDepartment of Urology, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Zonglin WuDepartment of Urology, Shanghai Shidong Hospital of Yangpu District, Shanghai, China.
Keyi WangDepartment of Urology, Shanghai Shidong Hospital of Yangpu District, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients diagnosed with papillary renal cell carcinoma (pRCC) exhibit a high rate of clinical metastasis; however, the underlying molecular mechanism is unclear. In this study, KH-type splicing regulatory protein (KHSRP) participated in pRCC progression and was associated with metastasis. It was positively correlated with the hallmark of epithelial-mesenchymal transition. KHSRP inhibition effectively alleviated the cellular function of migration and invasion. Additionally, KHSRP knockdown inhibited the proliferative ability of pRCC cells. A pharmaceutical screening was based on the KHSRP protein structure. Gemcitabine (Gem) decreased KHSRP expression. UIO-66@Gem@si-KHSRP (UGS) nanoparticles (NPs) were prepared for targeted delivery and applied in both

Indexed as

gemcitabineKHSRPmetastasispapillary renal cell carcinomatarget therapy

Identifiers

PMID39439895
PMCPMC11493689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.